原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识

2021-07-15 国家艾滋病和病毒性肝炎等重大传染病防治科技专项“中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究”课题组 临床肝胆病杂志

原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识

中文标题:

原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识

发布日期:

2021-07-15

简要介绍:

目前西医与中医处理TACE术后不良反应及并发症方面在遵循统一原则的情况下各有侧重,西医重视术后不良反应及并发症的预防和处理,中医在调整TACE术后患者的体能状态及个体化的康复治疗方面有明显优势,二者结合应用优势互补,可更好地促进TACE术后快速康复,减少并发症,提高疗效。中医药在减轻TACE术后不良反应、减少并发症方面具有独特的优势,但尚未形成统一意见。本共识由国家艾滋病和病毒性肝炎等重大传染病防治科技专项“中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究”课题组成员共同撰写,依托中国医师协会中西医结合分会肿瘤专业委员会、河南省康复医学会消化康复分会、河南省中西医结合学会肝病分会,组织相关专家讨论拟定了促进TACE术后快速康复的中西医结合专家意见。

相关资料下载:
[AttachmentFileName(sort=1, fileName=原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=73d381c002203a5e, title=原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识, enTitle=, guiderFrom=临床肝胆病杂志, authorId=0, author=, summary=原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识, cover=https://img.medsci.cn/20211013/1634094414737_5579292.jpg, journalId=0, articlesId=null, associationId=2004, associationName=国家艾滋病和病毒性肝炎等重大传染病防治科技专项“中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究”课题组, associationIntro=国家艾滋病和病毒性肝炎等重大传染病防治科技专项“中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究”课题组, copyright=0, guiderPublishedTime=Thu Jul 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">目前西医与中医处理TACE术后不良反应及并发症方面在遵循统一原则的情况下各有侧重,西医重视术后不良反应及并发症的预防和处理,中医在调整TACE术后患者的体能状态及个体化的康复治疗方面有明显优势,二者结合应用优势互补,可更好地促进TACE术后快速康复,减少并发症,提高疗效。中医药在减轻TACE术后不良反应、减少并发症方面具有独特的优势,但尚未形成统一意见。本共识由国家艾滋病和病毒性肝炎等重大传染病防治科技专项&ldquo;中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究&rdquo;课题组成员共同撰写,依托中国医师协会中西医结合分会肿瘤专业委员会、河南省康复医学会消化康复分会、河南省中西医结合学会肝病分会,组织相关专家讨论拟定了促进TACE术后快速康复的中西医结合专家意见。</span></p>, tagList=[TagDto(tagId=1097, tagName=原发性肝癌)], categoryList=[CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=92, categoryName=血管外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1097, guiderKeyword=原发性肝癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2671, appHits=102, showAppHits=0, pcHits=452, showPcHits=2568, likes=0, shares=18, comments=4, approvalStatus=1, publishedTime=Wed Oct 13 11:36:10 CST 2021, publishedTimeString=2021-07-15, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Oct 13 11:11:31 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Wed Jan 03 14:26:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识.pdf)])
原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207088, encodeId=f437120e08843, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:44:37 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075399, encodeId=e03310e5399a0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Tue Nov 30 11:33:36 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060099, encodeId=d486106009919, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Wed Oct 13 12:59:49 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060098, encodeId=bf6e1060098e5, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/fd684fe8990b45b491079e7402430e5c/172e645274a3412dada3473697e1344b.jpg, createdBy=020b5427427, createdName=imnfish, createdTime=Wed Oct 13 12:45:48 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-03-30 56446_2968

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207088, encodeId=f437120e08843, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:44:37 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075399, encodeId=e03310e5399a0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Tue Nov 30 11:33:36 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060099, encodeId=d486106009919, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Wed Oct 13 12:59:49 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060098, encodeId=bf6e1060098e5, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/fd684fe8990b45b491079e7402430e5c/172e645274a3412dada3473697e1344b.jpg, createdBy=020b5427427, createdName=imnfish, createdTime=Wed Oct 13 12:45:48 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1207088, encodeId=f437120e08843, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:44:37 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075399, encodeId=e03310e5399a0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Tue Nov 30 11:33:36 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060099, encodeId=d486106009919, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Wed Oct 13 12:59:49 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060098, encodeId=bf6e1060098e5, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/fd684fe8990b45b491079e7402430e5c/172e645274a3412dada3473697e1344b.jpg, createdBy=020b5427427, createdName=imnfish, createdTime=Wed Oct 13 12:45:48 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 ms3000001592172450

    受益匪浅!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207088, encodeId=f437120e08843, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:44:37 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075399, encodeId=e03310e5399a0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Tue Nov 30 11:33:36 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060099, encodeId=d486106009919, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Wed Oct 13 12:59:49 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060098, encodeId=bf6e1060098e5, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210806/fd684fe8990b45b491079e7402430e5c/172e645274a3412dada3473697e1344b.jpg, createdBy=020b5427427, createdName=imnfish, createdTime=Wed Oct 13 12:45:48 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 imnfish

    0